ADRIATIC

NCT03703297 📎

Regimen

Experimental
durvalumab 1500 mg q4w consolidation for up to 24 months
Control
placebo q4w

Population

Limited-stage SCLC without progression after concurrent platinum-based chemoradiotherapy

Key finding

mOS 55.9 vs 33.4 mo (HR 0.73, 98.321% CI 0.54-0.98, P=0.01); mPFS 16.6 vs 9.2 mo (HR 0.76, 97.195% CI 0.59-0.98, P=0.02)

Source: PMID 39268857

Timeline

    Guideline citations

    • NCCN SCLC (p.6)
    • CSCO SCLC 2025 (p.47)⚠️ OCR source